Related Experiment Video

Updated: Dec 30, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K

MicroRNA-612 inhibits cervical cancer progression by targeting NOB1

Yang Jin1, Xu Zhou2, Xiaoxiao Yao1

  • 1Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, The Second Hospital of Jilin University, Changchun, China.

Journal of Cellular and Molecular Medicine
|January 24, 2020
PubMed

Insights

MicroRNA-612 (miR-612) acts as a tumor suppressor in cervical cancer. Its reduced expression correlates with advanced disease, and restoring miR-612 inhibits cancer cell growth and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MicroRNA-612 (miR-612) has been implicated in various cancers, but its function in cervical cancer is not well understood.
  • Cervical cancer progression is a significant global health concern, necessitating research into novel therapeutic targets.

Purpose of the Study:

  • To investigate the biological role and molecular mechanisms of miR-612 in cervical cancer.
  • To determine if miR-612 can serve as a potential therapeutic target for cervical cancer.

Main Methods:

  • Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to assess miR-612 expression.
  • In vitro assays (proliferation, migration, invasion, apoptosis) and in vivo xenograft models to evaluate miR-612 function.
  • Bioinformatics, luciferase reporter assays, and Western blot to elucidate the miR-612/NOB1 interaction.

Main Results:

  • miR-612 expression was significantly downregulated in cervical cancer tissues and cell lines, correlating with FIGO stage and lymph node metastasis.
  • Overexpression of miR-612 suppressed cervical cancer cell proliferation, migration, and invasion in vitro, and inhibited tumor growth in vivo.
  • miR-612 directly targets nin one binding protein (NOB1), and NOB1 overexpression partially rescued the tumor-suppressive effects of miR-612.

Conclusions:

  • miR-612 functions as a tumor suppressor in cervical cancer by targeting NOB1.
  • Restoring miR-612 levels may represent a promising therapeutic strategy for cervical cancer treatment.
Keywords:
cervical cancerinvasionmiR-612nin one binding proteinproliferation

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.8K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
10.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K